IM Cannabis (IMC), an Israeli cannabis company, has decided to enter the European cannabis markets after receiving a permit to import 4 tons of cannabis into Germany. Moreover, the company is planning to expand its local business, signing an agreement with the largest pharmacy network in Israel, SuperPharm, to distribute 13.5 tons of cannabis over the next 3 years.
The Israeli cannabis company IMC is expanding its operations in Israel and around the world. In recent weeks, the company has received an extraordinary permit to import 4 tons of cannabis into Germany. In addition, the company has signed an agreement to distribute 13.5 tons of cannabis through Super-Pharm in Israel.
IMC, which brands itself abroad under the name of IM Cannabis and trades on the Canadian stock exchange worth $70 million (NIS 245 million), received a permit from the German Cannabis Authority (BfArM) to import four tons of cannabis. That is in addition to tens of kilograms that the company has been marketing from the Netherlands for six months.
If you want to know more about cannabis, how the cannabis industry in Israel is developing at a rapid pace, how Israeli companies expand not only locally but on a global scale, and to find out the latest hemp news, download the Hemp.im mobile application.
Entering the European market will benefit the Israeli cannabis industry
As said before, the veteran Israeli cannabis company IMC continues to expand in the global cannabis market as this week took a significant stake in the German cannabis market – the only European country to import cannabis blossoms and not just cannabis oils.
These four tons constitute a market share of about 40% of the entire German market at the moment, based on imports only. In 2019, a total of 7.5 tons were brought to Germany and it is expected that by 2020 up to 10 tons will be imported at most. Cannabis will be imported by its joint IMC in Spain.
The import to Germany will be made by the local Adjupharm company, which is (90%) owned by IMC and holds EU-GMP standards. It will market the produce in pharmacies in the country through three distribution companies with which the company has signed agreements to sell 825 kg already in the coming year.
According to a report from the stock exchange, the company intends to continue importing cannabis from Germany into the Dutch Droucan and the joint facility in Spain, as well as from the countries of Portugal, Canada and finally from Israel, which has not yet approved the export of cannabis abroad to this day.
IMC is also expanding its operations in Israel
In Israel, IMC is expected to expand after it recently signed an agreement worth $57 million (NIS 200 million) with the country’s largest pharmacy network SuperPharm to distribute 13.5 tons of cannabis over the next 3 years (2020-2022) – alongside private pharmacy agreements.
Since in Israel, about 20 to 25 tons of cannabis are sold per year, this is in fact about 20% of the local market. Along with the new permits in Germany and its operations in Spain, Canada, and more, the IMC is emerging as a company that may soon hold a respectable share of the world’s medical cannabis trade.
The IMC cannabis product inventory in Israel’s pharmacies has recently diminished, but according to the company’s estimates and based on the agreement with Super Pharm, the local market is likely to be flooded with its products in the coming months towards the end of 2020.
DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Hemp.im, its management, staff or its associates. Please review our disclaimer for more information.
This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.
First published in קנאביס, a third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.
Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Hemp.im assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Hemp.im is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.